Dango, Sebastian and Wang, Xiao Tao and Gold, Monika and Cucuruz, Beatrix and Klein, Christoph A. and Passlick, Bernward and Sienel, Wulf (2010) Expression of melanoma-antigen-A (MAGE-A) in disseminated tumor cells in regional lymph nodes of patients with operable non-small cell lung cancer. LUNG CANCER, 67 (3). pp. 290-295. ISSN 0169-5002,
Full text not available from this repository.Abstract
Purpose. Single disseminated tumor cells are detectable in regional lymph nodes of 30-50% patients with early-stage non-small cell lung cancer (NSCLC) This study investigated if these disseminated tumor cells express MACE-A and thus might be targeted by adjuvant anti-MACE-A immunotherapies. Experimental design Lymph nodes of 32 consecutive patients without neoadjuvant therapy were removed by systematic lymphadenectomy during resection of NSCLC One-hundred of these lymph nodes were cut Into two equal halves which were examined using either routine histo-pathology or quantitative reverse transcriptase PCR (qRT-PCR) qRT-PCR amplification of cytokeratin 19 transcripts was applied for the detection of disseminated tumor cells Expression of MACE-A was analyzed using one single primer pair amplifying subgroups MACE-A1 to -A6 in one qRT-PCR reaction Results. Ninety-four (94%) lymph nodes were tumor-free by histo-pathology qRT-PCR detected disseminated tumor cells in 26 (28%) of these lymph nodes resulting in 19 (59%) patients with disseminated tumor cells. All of the remaining 6 lymph nodes that were judged by the pathologist to contain tumor cells exhibited CK19 transcripts Fifteen (46%) lymph nodes with disseminated tumor cells contained MACE-A transcripts resulting in 12 (37%) patients with disseminated tumor cells which expressed MAGE-A There was no correlation between clinico-pathological parameters and the occurrence of disseminated tumor cells or their MACE-A expression Conclusions. Since 37% of patients with operable NSCLC harbored disseminated tumor cells that expressed MACE-A, only these patients might benefit from adjuvant immunotherapies directed against MAGE-A1 to -A6. This study may provide a basis for the preselection of patients to be Included in such immunotherapy trials after resection of NSCLC (C) 2009 Elsevier Ireland Ltd All rights reserved
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | POLYMERASE CHAIN-REACTION; VINORELBINE PLUS CISPLATIN; METASTATIC MELANOMA; GENE; IDENTIFICATION; CARCINOMA; PROLIFERATION; CHEMOTHERAPY; PROGRESSION; DIAGNOSIS; Non-small cell lung cancer (NSCLC); Lymph node metastasis; Melanoma-antigen (MAGE); Disseminated tumor cells (DTCs); Quantitative RT-PCR; Adjuvant immunotherapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Aug 2020 09:37 |
| Last Modified: | 05 Aug 2020 09:37 |
| URI: | https://pred.uni-regensburg.de/id/eprint/25101 |
Actions (login required)
 |
View Item |
